Somewhere around your 45th birthday, colon cancer screening stops being an abstract public health message and becomes something your doctor starts talking to you about. And if you follow health news, you might be genuinely confused about what you're supposed to do. A big trial in 2022 spawned headlines like "colonoscopies may not save lives." Then a 2025 trial said a simple at-home poop test works just as well as the camera.
So which is it? Do you need the scope, the stool kit, or neither?
Here's the short answer: both colonoscopy and the FIT stool test are legitimate, guideline-endorsed ways to screen, but every major US medical body still recommends colonoscopy as an option in 2026. The headlines misread what the big trial actually found. But at the end of the day, the best screening test is the one you actually complete.
Getting screened matters
Colorectal cancer is the second most common cause of cancer death in the US when men's and women's numbers are combined. The American Cancer Society expects about 109,000 new colon cancers and 50,000 new rectal cancers in 2026, and about 55,230 deaths.
The younger-adult trend is the part that should get your attention. Overall incidence has been falling about 1% a year, largely because of screening. But in people under 50, rates have been rising about 2.9% a year, and people born around 1990 carry about double the colon-cancer risk and quadruple the rectal-cancer risk of people born around 1950 - relative birth-cohort comparisons; absolute risk still rises strongly with age. Nobody has fully explained why.
Screening works when it happens because of how this cancer grows. Most colorectal cancers start as polyps, small growths that can take around a decade to turn cancerous - and most polyps never do. Removing precancerous polyps can prevent cancers from developing at all. And when cancer is caught while still localized, 5-year relative survival is 91% for colon cancer. Once it spreads to distant organs, that number falls to 13%.
The two tests
To help you get a sense of which test might be the better choice for you, let’s dig into what they are and how they’re different.
FIT (fecal immunochemical test)
FIT is an at-home stool test that detects hidden blood in your poop. You collect a sample, mail it in, done. No prep, no sedation, no time off. You repeat it every year.
In the large pooled USPSTF analysis, FIT caught about 74% of colorectal cancers with about 94% specificity, meaning few false alarms. Its blind spot is precancer: it detected only about 23% of advanced adenomas, the polyps most likely to become cancer, because most polyps don't bleed enough to detect. FIT is much better at finding existing cancer than precancerous polyps, so its effectiveness depends on repeating it on schedule and following every positive with a colonoscopy.
A positive FIT is not a diagnosis. It means you need a colonoscopy to find out what's going on. Skipping that follow-up throws away the entire point of testing, and the American Cancer Society says it should happen preferably within 6 months.
There's also a souped-up cousin: the stool DNA test (Cologuard) catches about 93% of cancers, with more false positives, every 3 years. A newer RNA-based version (ColoSense) joined the guidelines in 2026.
Colonoscopy
This one is the camera exam. A doctor threads a scope through your entire colon, finds polyps, and removes them on the spot. Detection and prevention in one procedure. If it's clean and you're average risk, you don't need another for 10 years.
The costs are real but modest. You do a bowel prep the day before (widely considered the worst part), you're usually sedated, you need a ride home, and you lose a day. Serious complications are uncommon: per USPSTF data, about 14.6 major bleeds and 3.1 perforations per 10,000 screening procedures.
The trial behind the "colonoscopy is dead" headlines
In October 2022, the NordICC trial landed in the New England Journal of Medicine: 84,585 people in Poland, Norway, and Sweden, ages 55 to 64, some invited to a screening colonoscopy, some not. After 10 years, the invited group had less colorectal cancer (0.98% vs 1.20%), but the difference in colon cancer deaths (0.28% vs 0.31%) was not statistically significant.
Cue the headlines. But here's what got lost: only 42% of the people invited actually got the colonoscopy. The trial mostly measured what happens when you offer colonoscopy to a population, not what happens when someone actually gets one. When the researchers estimated the effect for people who completed screening (a per-protocol analysis, which comes with its own biases in both directions), they found a 31% reduction in cancer risk and a 50% reduction in colon cancer deaths.
The 13-year results, published in The Lancet in May 2026: cancer incidence 1.46% in the invited group versus 1.80% in the control group, a 19% relative reduction, with the estimated effect around 45% if everyone invited had been screened. But colon cancer deaths, 0.41% versus 0.47%, remained not statistically significant.
One peer-reviewed reanalysis of the 10-year data found no significant survival benefit. The fairest summary: colonoscopy clearly prevents cancers. Whether inviting whole populations to colonoscopy saves lives is still being measured.
